Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

(2021) Stephen A. Harrison et al.   NATURE MEDICINE

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

(2021) Sven M. Francque et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

(2021) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

(2020) Rod S. Taylor et al.   GASTROENTEROLOGY

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

(2020) Vlad Ratziu et al.   HEPATOLOGY

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials

(2020) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Why do so many NASH trials fail?

(2020) Vlad Ratziu et al.   GASTROENTEROLOGY

Nonalcoholic Steatohepatitis

(2020) Adam C. Sheka et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus

(2020) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis

(2020) Guillaume Lassailly et al.   GASTROENTEROLOGY

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

(2020) Stephen A. Harrison et al.   GASTROENTEROLOGY

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

(2020) Beth A. Davison et al.   JOURNAL OF HEPATOLOGY

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

(2020) Rohit Loomba et al.   HEPATOLOGY

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis

(2019) Stephen A. Harrison et al.   HEPATOLOGY

FGF19 Analogue as a Surgical Factor Mimetic that Contributes to Metabolic Effects Beyond Glucose Homeostasis

(2019) Alex M. DePaoli et al.   DIABETES

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

(2018) Stephen A. Harrison et al.   GASTROENTEROLOGY

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

(2018) Chris Estes et al.   JOURNAL OF HEPATOLOGY

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2018) Stephen A Harrison et al.   LANCET

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

(2017) Chris Estes et al.   HEPATOLOGY

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

(2016) Juan P. Arab et al.   HEPATOLOGY

Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

(2015) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Bile Acids as Hormones: The FXR-FGF15/19 Pathway

(2015) Steven A. Kliewer et al.   DIGESTIVE DISEASES

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

(2015) Guillaume Lassailly et al.   GASTROENTEROLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

(2015) Chiara Degirolamo et al.   NATURE REVIEWS DRUG DISCOVERY

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19

(2014) M. Zhou et al.   CANCER RESEARCH

Total Body Weight Loss of ≥10 % Is Associated with Improved Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis

(2014) Lisa M. Glass et al.   DIGESTIVE DISEASES AND SCIENCES

A nontumorigenic variant of FGF19 treats cholestatic liver diseases

(2014) J. Luo et al.   Science Translational Medicine